Home Luminex Corporation

Luminex Corporation

Luminex Provides Updates on Critical Efforts Related to Novel Coronavirus

"We have been working on multiple solutions to augment our NxTAG and ARIES offerings in order to facilitate and automate the detection of SARS-CoV-2," said Nachum "Homi" Shamir, President and CEO of Luminex.

Luminex Corporation Submits VERIGENE® II Respiratory Flex Assay for FDA Clearance

Luminex Corporation today announced they submitted an application to the FDA for 510(k) clearance of the VERIGENE® II Respiratory Flex Assay, the second VERIGENE II assay to be submitted to the agency. The VERIGENE® II Respiratory Flex (RSP Flex) Assay is a multiplexed, qualitative test for simultaneous detection and identification of common viruses and bacteria from nasopharyngeal swabs that are obtained from individuals suspected of respiratory tract infection.